Related Experiment Video
Updated: May 27, 2026
Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
Published on: January 10, 2025
Inhibition of miR-15 protects against cardiac ischemic injury
Thomas G Hullinger1, Rusty L Montgomery, Anita G Seto
1miRagen Therapeutics, Inc, 6200 Lookout Rd, Boulder, CO 80301, USA.
Rationale:
Myocardial infarction (MI) is a leading cause of death worldwide. Because endogenous cardiac repair mechanisms are not sufficient for meaningful tissue regeneration, MI results in loss of cardiac tissue and detrimental remodeling events. MicroRNAs (miRNAs) are small, noncoding RNAs that regulate gene expression in a sequence dependent manner. Our previous data indicate that miRNAs are dysregulated in response to ischemic injury of the heart and actively contribute to cardiac remodeling after MI.
Objective:
This study was designed to determine whether miRNAs are dysregulated on ischemic damage in porcine cardiac tissues and whether locked nucleic acid (LNA)-modified anti-miR chemistries can target cardiac expressed miRNAs to therapeutically inhibit miR-15 on ischemic injury.
Methods And Results:
Our data indicate that the miR-15 family, which includes 6 closely related miRNAs, is regulated in the infarcted region of the heart in response to ischemia-reperfusion injury in mice and pigs. LNA-modified chemistries can effectively silence miR-15 family members in vitro and render cardiomyocytes resistant to hypoxia-induced cardiomyocyte cell death. Correspondingly, systemic delivery of miR-15 anti-miRs dose-dependently represses miR-15 in cardiac tissue of both mice and pigs, whereas therapeutic targeting of miR-15 in mice reduces infarct size and cardiac remodeling and enhances cardiac function in response to MI.
Conclusions:
Oligonucleotide-based therapies using LNA-modified chemistries for modulating cardiac miRNAs in the setting of heart disease are efficacious and validate miR-15 as a potential therapeutic target for the manipulation of cardiac remodeling and function in the setting of ischemic injury.
Insights
MicroRNAs (miRNAs) are dysregulated after heart attacks. Targeting the miR-15 family with LNA-modified anti-miRs reduced heart damage and improved function in preclinical models of myocardial infarction (MI).
Area of Science:
- Cardiovascular Research
- Molecular Biology
- RNA Therapeutics
Background:
- Myocardial infarction (MI) leads to significant cardiac tissue loss and adverse remodeling due to insufficient endogenous repair.
- MicroRNAs (miRNAs) are implicated in regulating gene expression and are known to be dysregulated following cardiac ischemic injury, contributing to post-MI remodeling.
Purpose of the Study:
- To investigate miRNA dysregulation in porcine cardiac tissue following ischemic damage.
- To evaluate the therapeutic potential of locked nucleic acid (LNA)-modified anti-miRs for inhibiting miR-15 in the context of ischemic heart injury.
Main Methods:
- Investigated the miR-15 family's regulation in response to ischemia-reperfusion injury in mouse and pig hearts.
- Assessed the efficacy of LNA-modified anti-miR-15 in vitro for silencing miR-15 and protecting cardiomyocytes from hypoxia.
- Evaluated the in vivo effects of systemic anti-miR-15 delivery on miR-15 repression, infarct size, cardiac remodeling, and function in mice.
Main Results:
- The miR-15 family was found to be regulated in infarcted cardiac regions of both mice and pigs.
- LNA-modified anti-miRs effectively silenced miR-15 family members in vitro, conferring resistance to hypoxia-induced cardiomyocyte death.
- Systemic delivery of anti-miR-15 dose-dependently repressed miR-15 in cardiac tissue and reduced infarct size, cardiac remodeling, and improved cardiac function in mice post-MI.
Conclusions:
- Oligonucleotide-based therapies utilizing LNA-modified chemistries are effective for modulating cardiac miRNAs in heart disease.
- miR-15 is validated as a promising therapeutic target for managing cardiac remodeling and function after ischemic injury.